Business
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (C...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs\n\n\n\n\n Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial.\n \n\n\n\n Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.\n \n\n RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.\n \n\n Eupraxia intends to expand the EP-104GI development program, including increasing the number of patients in the Phase 2b portion of RESOLVE from 60 to at least 120 patients.\n \n\n Eupraxia intends to initiate a clinical trial for an additional market-expanding GI indication in the first half of 2026.\n \n\n Eupraxia will host a webinar on October 1\n \n st\n \n at 8am PDT to provide additional information. The live webinar is available at:\n \n https://lifescievents.com/event/fk30t7wg2n/\n \n\n\n\n VICTORIA, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today provided an operational update on the development of EP-104GI, including reporting data from patients in Cohort 9 of the dose escalation portion of the RESOLVE trial, the first time that patients received an 8mg dose per injection.\n \n\n “We believe our recent financing, combined with our latest clinical trial results, underscores both the medical and investment communities’ confidence in EP-104GI. The strong efficacy trend observed in previous cohorts – the more drug we deliver to the tissue, the better the results we observe – has continued in Cohort 9. Combined with the absence of any Serious Adverse Events or cases of candidiasis, this strongly suggests that an 8mg dose per injection is the optimal second dose to test in o...